Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Information provided by:
Isala Identifier:
First received: April 5, 2006
Last updated: August 25, 2009
Last verified: August 2009

Treatment with systemic corticosteroids for acute exacerbations of COPD results in the improvement of clinical outcomes. The optimal route of administration has not been rigorously studied in COPD. Upon hospitalization, corticosteroids are administered intravenously in many hospitals. Oral administration is more convenient, though, because there is no need for intravenous access, less personnel is required for starting and monitoring therapy, and material costs are smaller.

The investigators hypothesized that oral administration is not inferior to intravenous administration of prednisolone in the treatment of patients hospitalized for an acute exacerbation of COPD.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Intravenous prednisolone
Drug: Oral prednisolone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by Isala:

Primary Outcome Measures:
  • Treatment failure defined as: death from any cause
  • admission to the intensive care unit
  • readmission to the hospital because of COPD
  • and the necessity to intensify pharmacologic treatment

Secondary Outcome Measures:
  • Changes in forced expiratory volume in 1 second (FEV1)
  • St. George's Respiratory Questionnaire (SGRQ) scores
  • Clinical COPD Questionnaire (CCQ) scores
  • and length of hospital stay

Estimated Enrollment: 256
Study Start Date: June 2001
Study Completion Date: August 2003
Primary Completion Date: August 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Exacerbation of COPD (at least Global Initiative for Chronic Obstructive Lung Disease [GOLD] severity stage II)
  • Smoking history of > 10 pack years

Exclusion Criteria:

  • Signs of severe exacerbation (arterial pH < 7.26 or pCO2 > 9.3 kPa)
  • History of asthma
  • Significant or unstable co-morbidity
  • Participated in another study 4 weeks before admission
  • Previously randomized to this study
  • Findings on chest radiography other than those fitting with signs of COPD
  • Known hypersensitivity to prednisolone
  • Non-compliant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00311961

Isala Klinieken
Zwolle, Overijssel, Netherlands, 8000 GM
Sponsors and Collaborators
Principal Investigator: Jan WK van den Berg, MD, PhD Isala
Principal Investigator: Ynze P de Jong, MD Isala
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00311961     History of Changes
Other Study ID Numbers: IK-001
Study First Received: April 5, 2006
Last Updated: August 25, 2009

Keywords provided by Isala:
Chronic Obstructive Pulmonary Disease (COPD)

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents processed this record on April 26, 2017